HLE BiTE® technology: enhancing features of the BiTE® platform
Engineering BiTE® molecules with a longer half-life
Bispecific T Cell Engager (BiTE®) technology is designed to overcome cancer cells' evasion of the immune system by engaging patients’ own T cells to directly target cancer cells.1,2 BiTE® molecules are engineered to target a selected tumor-associated antigen and CD3 found on T cells.3,4 Canonical BiTE® molecules are designed to be relatively small recombinant proteins that could be cleared through the kidney, with a typical serum half-life of a few hours.3,5
Currently, Amgen is designing half-life extended (HLE) BiTE® molecules containing fragment-crystallizable (Fc) domains.6 Adding an Fc portion to a BiTE® molecule is designed to extend the amount of time before it is eliminated from the body.7,8
Search our clinical trials.
Visit our resources section for further information on modalities currently under investigation.
Extending the benefits of BiTE® technology
Canonical BiTE® molecules are designed to be relatively small recombinant proteins that are cleared through the kidney, with a serum half-life of a few hours. Currently, the protein engineers at Amgen are designing BiTE® molecules with enhanced features, including a half-life extended (HLE) BiTE® molecule containing a fragment-crystallizable (Fc) domain. Adding an Fc portion to the BiTE® molecule is designed to extend the amount of time before it is eliminated from the body.1-3,5-7
BCMA: B-cell maturation antigen; BiTE: Bispecific T Cell Engager; CD: cluster of differentiation; CLDN18.2: Claudin-18 isoform 2; DLL3: delta-like protein 3; FLT3: FMS-like tyrosine kinase 3; GEJ: gastroesophageal junction; HLE: half-life extended; MUC17: mucin17; PSMA: prostate-specific membrane antigen.
1. Baeuerle PA, Kufer P, Bargou R. Curr Opin Mol Ther. 2009;11(1):22-30. 2. Frankel SR, Baeuerle PA. Curr Opin Chem Biol. 2013;17(3):385-392. 3. Yuraszeck T, Kasichayanula S, Benjamin JE. Clin Pharmacol Ther. 2017;101(5):634-645. 4. Nagorsen D, Baeuerle PA. Exp Cell Res. 2011;317(9):1255-1260. 5. Thakur A, Huang M, Lum LG. Blood Rev. 2018;32(4):339-347. 6. Raum T, Münz M, Brozy J, inventors. US Patent 2017/0218077A1. 8/3/2017. 7. Weidle UH, Tiefenthaler G, Weiss EH, et al. Cancer Genomics Proteomics. 2013;10(1):1-18. 8. Arvedson TL, Balazs M, Bogner P, et al. Cancer Res. 2017;77(suppl 13):Abstract 55. 9. Ferrone S, Whiteside TL. Surg Oncol Clin N Am. 2007;16(4):755-774. 10. Baeuerle PA, Reinhardt C. Cancer Res. 2009;69(12):4941-4944. 11. Brischwein K, Schlereth B, Guller B, et al. Mol Immunol. 2006;43(8):1129-1143. 12. Amgen. Amgen pipeline. https://www.amgenpipeline.com/-/media/themes/amgen/amgenpipeline-com/amgenpipeline-com/pdf/amgen-pipeline-chart.pdf. Accessed 4/8/2020. 13. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04260191. Accessed 4/21/2020.